Search
Kids born with Down syndrome are at high risk of an array of health problems. One of the lesser-known complications is their increased risk of childhood leukaemia.
Pineoblastoma is a rare brain tumor usually diagnosed in children. Given its rarity, no pineoblastoma-specific trials have been conducted. Studies have included pineoblastoma accruing for other embryonal tumors over the past 30 years.
Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies.
The outcome of infants with KMT2A-germline acute lymphoblastic leukaemia (ALL) is superior to that of infants with KMT2A-rearranged ALL but has been inferior to non-infant ALL patients. Here, we describe the outcome and prognostic factors for 167 infants with KMT2A-germline ALL enrolled in the Interfant-06 study.
Co-Head, Leukaemia Translational Research
Co-Head, Leukaemia Translational Research
Honorary Emeritus Fellow
We provide evidence that targeting leukemia-induced bone loss is a therapeutic strategy for pre-B ALL
This study utilized in vitro, in vivo and clinical data to evaluate the palatability of a novel midazolam chocolate tablet.
latent neural precursor cells remain present in the neurogenic niche of the adult hippocampus up to 8 weeks following high-dose total body irradiation